Kedokteran & Kesehatan editorial
Open AccessOA2022
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
A randomized controlled trial demonstrates that fecal microbiota transplantation (FMT) reduces liver fat accumulation in NAFLD patients by improving gut dysbiosis, with superior clinical and microbiota outcomes in lean compared to obese NAFLD patients.
L. Xue; Zhiliang Deng; Wen-Hui Luo; Xing-Xiang He; Yu Chenยท Frontiers in Cellular and Infection Microbiologyยท 2022ยท DOI 10.3389/fcimb.2022.759306
The core problem
Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited effective treatments. The gut-liver axis plays a critical role in NAFLD pathogenesis, and fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy. However, the clinical efficacy of FMT in NAFLD and its differential effects on lean versus obese patients remain unclear. This study aimed to determine the clinical efficacy and safety of FMT in NAFLD patients and to elucidate its varying influences on lean and obese subgroups.
Innovation
This was a randomized, controlled clinical trial. Patients in the non-FMT group received oral probiotics. In the FMT group, patients were randomized to receive heterologous donor stool via colonoscopy, followed by three enemas over 3 days. Both groups were instructed to maintain a healthy diet and engage in regular exercise for more than 40 minutes daily. Patients returned for reexamination 1 month after treatment. The study assessed clinical features, gut microbiota composition, and liver fat accumulation.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited effective treatments. The gut-liver axis plays a critical role in NAFLD pathogenesis, and fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy. However, the clinical efficacy of FMT in NAFLD and its differential effects on lean versus obese patients remain unclear. This study aimed to determine the clinical efficacy and safety of FMT in NAFLD patients and to elucidate its varying influences on lean and obese subgroups.
Why it matters
The findings indicate that FMT is a promising therapeutic approach for NAFLD, with its efficacy modulated by host metabolic status. The superior response in lean NAFLD patients suggests that body mass index may influence the engraftment and functional impact of donor microbiota. The study underscores the importance of personalized treatment strategies in NAFLD and highlights the need for further research to optimize FMT protocols for obese patients. The safety profile of FMT was not explicitly detailed in the abstract, but the procedure was well-tolerated as per the trial design.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ